Details for Patent: 10,654,827
Which drugs does patent 10,654,827 protect, and when does it expire?
Patent 10,654,827 protects SUNLENCA, BIXLENVO, and BIXLENVO SUNLENCA STARTER PACK (COPACKAGED), and is included in four NDAs.
This patent has ninety-seven patent family members in forty-five countries.
Summary for Patent: 10,654,827
| Title: | Therapeutic compounds |
| Abstract: | The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus. |
| Inventor(s): | Michael Graupe, Steven J. Henry, John O. Link, Roland D. SAITO, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US16/016,718 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,654,827
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Start Trial | ||||
| Gilead Sciences Inc | BIXLENVO | bictegravir sodium; lenacapavir sodium | TABLET;ORAL | 221104-001 | Aug 27, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN | ⤷ Start Trial | ||||
| Gilead Sciences Inc | BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) | bictegravir sodium, lenacapavir sodium; lenacapavir sodium | TABLET;ORAL | 221443-001 | Aug 27, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF HIV-1 IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN | ⤷ Start Trial | ||||
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,654,827
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3347352 | ⤷ Start Trial | CA 2022 00052 | Denmark | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | 301212 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | PA2023501 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3347352 | ⤷ Start Trial | 122022000082 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
